Leukocyte Cathepsin S Is a Potent Regulator of Both Cell and Matrix Turnover in Advanced Atherosclerosis | Zendy

R. de Nooijer | Zendy; Ilze Bot | Zendy; Jan H. von der Thüsen | Zendy; Michiel A. Leeuwenburgh | Zendy; Herman S. Overkleeft | Zendy; A. O. Kraaijeveld | Zendy; Rebecca B. Dorland | Zendy; Peter J. van Santbrink | Zendy; Sandra H. van Heiningen | Zendy; Marijke M. Westra | Zendy; Petri T. Kovanen | Zendy; J. Wouter Jukema | Zendy; E. E. van der Wall | Zendy; Th.J.C. van Berkel | Zendy; GuoPing Shi | Zendy; E.A.L. Biessen | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Leukocyte Cathepsin S Is a Potent Regulator of Both Cell and Matrix Turnover in Advanced Atherosclerosis

Author(s) -

R. de Nooijer,

Ilze Bot,

Jan H. von der Thüsen,

Michiel A. Leeuwenburgh,

Herman S. Overkleeft,

A. O. Kraaijeveld,

Rebecca B. Dorland,

Peter J. van Santbrink,

Sandra H. van Heiningen,

Marijke M. Westra,

Petri T. Kovanen,

J. Wouter Jukema,

E. E. van der Wall,

Th.J.C. van Berkel,

GuoPing Shi,

E.A.L. Biessen

Publication year - 2008

Publication title -

arteriosclerosis thrombosis and vascular biology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.007

H-Index - 270

eISSN - 1524-4636

pISSN - 1079-5642

DOI - 10.1161/atvbaha.108.181578

Subject(s) - cats , cathepsin , proteases , fibronectin , macrophage , pathology , lesion , apoptosis , cathepsin l , biology , chemistry , microbiology and biotechnology , extracellular matrix , medicine , biochemistry , in vitro , enzyme

A dysbalance of proteases and their inhibitors is instrumental in remodeling of atherosclerotic plaques. One of the proteases implicated in matrix degradation is cathepsin-S (CatS). To address its role in advanced lesion composition, we generated chimeric LDLr(-/-) mice deficient in leukocyte CatS by transplantation with CatS(-/-)xLDLr(-/-) or with LDLr(-/-) bone marrow and administered a high-fat diet.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research